Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Más betegség

• Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic coma or -pre-coma, metabolic acidosis including lactic acidosis and diabetic ketoacidosis
• Patients with a medical history of New York Heart Association(NYHA) class III~IV heart failure or with congestive heart failure, acute and unstable heart failure
• Patients with severe infectious disease or severe traumatic systemic disorders
• Patients with hypopituitarism or adrenal insufficiency, pulmonary infarction, severe pulmonary dysfunction and other hypoxemia

Egyéb

• Patients with galactose intolerance, lapp lactase deficiency, glucosegalactose malabsorption

• Patients with type II diabetes mellitus aged 19 years or older
• Patients who had taken DA5221-B1 and DA5221-B2(or another DPP-4 inhibitor is allowed) combination therapy at the same dose for at least 8 weeks prior to the screening visit
• Patients with fasting plasma glucose≤270mg/dL at the screening visit
• Patients with 18.5kg/m\^2≤BMI≤40kg/m\^2 at the screening visit
• Patients who have signed an informed consent themselves after receiving detailed explanation about the clinical study